Transforming Overwhelming Pharmaceutical Data into Actionable Insights with Jeffrey Freedman

In the healthcare sector, the pharmaceutical industry is facing a unique challenge: an abundance of data but a scarcity of actionable insights. Jeffrey Freedman, Executive Vice President at Evolution Health Group, recently addressed this issue in the Disruption Interruption podcast, hosted by Karla Jo Helms (KJ). He argues that although pharmaceutical companies are rich in data, they are still struggling to connect important entities such as doctors, patients, and educational resources effectively. This podcast episode sheds light on how artificial intelligence (AI) can be the game-changer in transforming data overload into meaningful insights.

The Overabundance of Data

Freedman highlights that the pharmaceutical industry possesses numerous streams of interaction data, research findings, physician engagement metrics, and patient behavior analytics. Yet, extracting meaningful insights from this data has proven to be a slow and painful process. He points out that the industry’s traditional reliance on disconnected databases—often taking the form of outdated spreadsheets—contributes significantly to the fragmentation that slows down progress. Freedman bluntly states, “When employees work off separate spreadsheets and siloed data, stuff gets lost… You don’t know what is happening on the other side of the world.”

The core issue runs deeper than just data visibility. Freedman critiques the industry’s reliance on direct-to-consumer marketing, arguing that financial resources should be allocated to educate physicians more effectively rather than concentrating efforts on patient-targeted advertising. He insists, “We don’t want patients all the time coming to a doctor and saying, ‘I need a GLP-1.’ We want the doctor saying to a patient, ‘You have these issues; let’s talk about how to make you better.’” This approach raises the important question of whether the right medical education is reaching the appropriate audience promptly to enhance patient outcomes.

A Prescription for Insight

Rather than advocating for merely collecting more data, Freedman underscores the need for improved systems that convert existing data into actionable insights. “You have to know how to ask the right questions,” he emphasizes. The role of AI, in this context, is to help teams identify the proper physicians, key opinion leaders, and pertinent signals that necessitate action. Freedman believes that enhancing insight and speeding up communication will facilitate quicker transitions from bench to bedside, especially for therapies addressing rare and costly diseases. “We want the cost of medicine to go down,” he explains, refining the focus on using technology to reduce noise, expedite learning processes, and empower doctors to make informed decisions for their patients.

At Evolution Health Group, Freedman’s vision manifests in innovative platforms designed to streamline communication and insights. He describes the organization as an “insight generation company,” employing various analytical tools to identify key opinion leaders and aggregate fragmented data into cohesive sources of truth. Platforms like 360 Connects and 360 KOL aim to close the communication gap between pharmaceutical brands and healthcare providers, making the entire process more transparent and efficient.

Confronting Misconceptions

Freedman desires to overcome the commonly held perception of the pharmaceutical industry as a formidable entity resistant to change. “Pharma is not this big scary monster that’s put out there in the media. It's a bunch of people that really care,” he asserts, aiming to create a better understanding of the industry’s motives and objectives.

If the insights drawn from this podcast episode are any indication, the marriage of AI technology and pharmaceutical data may very well be the path forward, empowering industry leaders to transform information overload into impactful medical advancements. Davidson & Freedman’s insightful discussion on the challenges facing pharma illustrates the importance of adapting to new technologies that promise to make significant improvements in the industry. The future appears bright for a sector poised to redefine how it processes and utilizes vital information to optimize patient outcomes.

For more in-depth discussions on innovation and disruption in various industries, listen to the full episode of the Disruption Interruption podcast and learn more about the visionaries leading these changes.